DE60001510T2 - Regioselektive synthese von rapamycinderivaten - Google Patents

Regioselektive synthese von rapamycinderivaten

Info

Publication number
DE60001510T2
DE60001510T2 DE60001510T DE60001510T DE60001510T2 DE 60001510 T2 DE60001510 T2 DE 60001510T2 DE 60001510 T DE60001510 T DE 60001510T DE 60001510 T DE60001510 T DE 60001510T DE 60001510 T2 DE60001510 T2 DE 60001510T2
Authority
DE
Germany
Prior art keywords
rapamycin
acid
carbon atoms
ether
silyl ether
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60001510T
Other languages
German (de)
English (en)
Other versions
DE60001510D1 (de
Inventor
Karen Cheal
Genevieve Fortier
Razzak Noureldin
Hamilton Sellstedt
Chia-Cheng Shaw
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth LLC
Original Assignee
Wyeth LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth LLC filed Critical Wyeth LLC
Application granted granted Critical
Publication of DE60001510D1 publication Critical patent/DE60001510D1/de
Publication of DE60001510T2 publication Critical patent/DE60001510T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE60001510T 1999-09-29 2000-09-27 Regioselektive synthese von rapamycinderivaten Expired - Lifetime DE60001510T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40883099A 1999-09-29 1999-09-29
PCT/US2000/026445 WO2001023395A2 (en) 1999-09-29 2000-09-27 Regioselective synthesis of rapamycin derivatives

Publications (2)

Publication Number Publication Date
DE60001510D1 DE60001510D1 (de) 2003-04-03
DE60001510T2 true DE60001510T2 (de) 2003-10-02

Family

ID=23617953

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60001510T Expired - Lifetime DE60001510T2 (de) 1999-09-29 2000-09-27 Regioselektive synthese von rapamycinderivaten

Country Status (24)

Country Link
EP (1) EP1216251B1 (enExample)
JP (1) JP4289813B2 (enExample)
KR (1) KR100754236B1 (enExample)
CN (1) CN1176925C (enExample)
AR (1) AR029181A1 (enExample)
AT (1) ATE233269T1 (enExample)
AU (1) AU782234B2 (enExample)
BR (1) BR0014433A (enExample)
CA (1) CA2385461C (enExample)
CZ (1) CZ300368B6 (enExample)
DE (1) DE60001510T2 (enExample)
DK (1) DK1216251T3 (enExample)
EA (1) EA004331B1 (enExample)
ES (1) ES2189768T3 (enExample)
HK (1) HK1044774B (enExample)
HU (1) HUP0202609A3 (enExample)
IL (2) IL148542A0 (enExample)
MX (1) MXPA02003243A (enExample)
NO (1) NO20021360L (enExample)
NZ (1) NZ517644A (enExample)
PL (1) PL200899B1 (enExample)
TW (1) TWI256395B (enExample)
WO (1) WO2001023395A2 (enExample)
ZA (1) ZA200201918B (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070032853A1 (en) 2002-03-27 2007-02-08 Hossainy Syed F 40-O-(2-hydroxy)ethyl-rapamycin coated stent
US20050118344A1 (en) 2003-12-01 2005-06-02 Pacetti Stephen D. Temperature controlled crimping
AU2004270154A1 (en) * 2003-09-03 2005-03-17 Wyeth Amorphous rapamycin 42-ester with 3-hydroxy-2-(hydroxymethyl)-2-methylpropionic acid and its pharmaceutical compositions containing the same
AR046194A1 (es) 2003-11-04 2005-11-30 Mayo Foundation Metodo de tratamiento del linfoma de celulas del manto
JP2007532650A (ja) 2004-04-14 2007-11-15 ワイス プロリンｃｃｉ−７７９（２，２−ビス（ヒドロキシメチル）プロピオン酸とのプロリン−ラパマイシン４２−エステル）ならびに細菌リパーゼを使用するプロリンｃｃｉ−７７９およびｃｃｉ−７７９の二段階酵素的合成
CN1942476A (zh) 2004-04-14 2007-04-04 惠氏公司 纳巴霉素42－酯衍生物的区位特异合成
CN1993368A (zh) 2004-08-10 2007-07-04 惠氏公司 Cci－779衍生物和其制备方法
RU2405566C9 (ru) 2005-02-03 2012-04-27 Дзе Дженерал Хоспитал Корпорейшн Способ лечения рака, устойчивого к гефитинибу
JP2008530090A (ja) 2005-02-09 2008-08-07 ワイス Ｃｃｉ−７７９多形及びその使用
PE20070763A1 (es) 2005-11-04 2007-08-08 Wyeth Corp COMBINACIONES ANTINEOPLASICAS DE UN INHIBIDOR DE mTOR, TRASTUZUMAB Y/O HKI-272
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
DK2310011T3 (da) 2008-06-17 2013-10-14 Wyeth Llc Antineoplastiske kombinationer indeholdende hki-272 og vinorelbin
CN101676291B (zh) 2008-09-18 2012-05-09 上海海和药物研究开发有限公司 一类雷帕霉素碳酸酯类似物、其药物组合物及其制备方法和用途
EP2528906A2 (en) * 2010-01-28 2012-12-05 Fresenius Kabi Oncology Ltd Process for the preparation of temsirolimus and its intermediates
CN102020662B (zh) 2011-01-07 2013-02-13 天津市炜杰科技有限公司 一种驮瑞塞尔制备方法
MX2013011412A (es) * 2011-04-01 2014-04-30 Sandoz Ag Acilacion regioselectiva de rapamicina en la posicion c-42.
CN103421023B (zh) * 2013-07-30 2015-09-23 福建省微生物研究所 一种替西罗莫司的合成工艺
CN104086564B (zh) * 2014-07-30 2019-02-05 江苏奥赛康药业股份有限公司 一种高纯度坦罗莫司的制备方法
CN106146536B (zh) * 2015-04-25 2019-07-26 山东新时代药业有限公司 一种依维莫司的制备方法
CN109562187B (zh) * 2016-03-14 2022-05-17 威斯康星校友研究基金会 具有增强的抗癌功效的低聚乳酸缀合物和胶束
CN107561170B (zh) * 2016-07-02 2021-07-30 山东新时代药业有限公司 一种坦西莫司中间体的分析检测方法
CN108948045A (zh) * 2017-05-20 2018-12-07 鲁南制药集团股份有限公司 一种替西罗莫司的制备方法
CN108948046B (zh) * 2017-05-20 2020-11-10 鲁南制药集团股份有限公司 一种替西罗莫司的中间体及其制备方法
CN109206441B (zh) * 2017-06-30 2022-05-20 正大天晴药业集团股份有限公司 一种依维莫司的纯化方法
CN109776570A (zh) * 2017-11-14 2019-05-21 上海医药工业研究院 一种依维莫司中间体、其制备方法及其应用
SG11202012447YA (en) 2018-06-15 2021-01-28 Navitor Pharm Inc Rapamycin analogs and uses thereof
CN109369679A (zh) * 2018-12-24 2019-02-22 江苏卓和药业有限公司 一种雷帕霉素的精制方法
CN109851626B (zh) * 2019-01-08 2021-11-02 扬子江药业集团四川海蓉药业有限公司 一种替西罗莫司的分离纯化方法
TW202134234A (zh) 2019-12-05 2021-09-16 美商奈維特製藥公司 雷帕黴素類似物及其用途
CN113372359A (zh) * 2020-03-10 2021-09-10 鲁南制药集团股份有限公司 一种坦西莫司的制备方法
CN114106014B (zh) * 2020-08-27 2024-03-15 鲁南制药集团股份有限公司 一种依维莫司的制备方法
CN115028658A (zh) * 2022-07-06 2022-09-09 国药集团川抗制药有限公司 雷帕霉素硅醇酯及其制备方法和应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5120842A (en) * 1991-04-01 1992-06-09 American Home Products Corporation Silyl ethers of rapamycin
US5387680A (en) * 1993-08-10 1995-02-07 American Home Products Corporation C-22 ring stabilized rapamycin derivatives
US5362718A (en) * 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
US5563145A (en) * 1994-12-07 1996-10-08 American Home Products Corporation Rapamycin 42-oximes and hydroxylamines

Also Published As

Publication number Publication date
KR20020029796A (ko) 2002-04-19
NO20021360D0 (no) 2002-03-19
JP2003510329A (ja) 2003-03-18
EA004331B1 (ru) 2004-04-29
CZ20021136A3 (cs) 2002-06-12
CN1176925C (zh) 2004-11-24
JP4289813B2 (ja) 2009-07-01
IL148542A (en) 2006-08-20
CA2385461A1 (en) 2001-04-05
AU7718200A (en) 2001-04-30
DK1216251T3 (da) 2003-06-16
EP1216251A2 (en) 2002-06-26
ZA200201918B (en) 2003-08-27
AU782234B2 (en) 2005-07-14
HK1044774B (en) 2003-05-30
ES2189768T3 (es) 2003-07-16
CN1402731A (zh) 2003-03-12
IL148542A0 (en) 2002-09-12
CZ300368B6 (cs) 2009-05-06
EP1216251B1 (en) 2003-02-26
HK1044774A1 (en) 2002-11-01
WO2001023395A3 (en) 2001-10-25
HUP0202609A2 (hu) 2002-12-28
TWI256395B (en) 2006-06-11
ATE233269T1 (de) 2003-03-15
NO20021360L (no) 2002-03-19
BR0014433A (pt) 2002-06-11
DE60001510D1 (de) 2003-04-03
HUP0202609A3 (en) 2004-11-29
WO2001023395A2 (en) 2001-04-05
CA2385461C (en) 2009-03-17
KR100754236B1 (ko) 2007-09-03
MXPA02003243A (es) 2002-09-30
PL354461A1 (en) 2004-01-12
AR029181A1 (es) 2003-06-18
EA200200412A1 (ru) 2002-10-31
PL200899B1 (pl) 2009-02-27
NZ517644A (en) 2003-09-26

Similar Documents

Publication Publication Date Title
DE60001510T2 (de) Regioselektive synthese von rapamycinderivaten
US6277983B1 (en) Regioselective synthesis of rapamycin derivatives
DE69521438T2 (de) Rapamycin 42-oxime und hydroxylamine
DE69408678T2 (de) C-22 ringstabilisierte rapamycin derivate
DE602004007145T2 (de) Regioselektive synthese von cci-779
DE69529897T3 (de) 42-rapamycin hydroxyester, verfahren zu dessen herstellung und diesen enthaltende pharmazeutische zusammensetzungen
DE69430586T2 (de) Aminoalkanester von rapamycin
DE69521907T2 (de) Gehinderte n-oxid ester von rapamycin und ihre verwendung als arzneimittel
EP0638082A1 (en) Macrocyclic immunomodulators
WO1998009972A1 (en) Rapamycin derivatives with unnatural stereochemistries
DE69306585T2 (de) 27 hydroxyrapamycin und derivate davon
DE60010476T2 (de) Verfahren zur Herstellung eines C-4-Methylcarbonat-Analogons von Paclitaxel
DE69231215T2 (de) Reduktionsprodukte von Rapamycin als immunosuppressive, entzündungshemmende und antifungale Mittel
EP0203216A1 (de) Penicillin-Derivate und Verfahren zu deren Herstellung
DE3408196C2 (enExample)
FI83654B (fi) Framstaellningsfoerfarande foer 2-(1-oxo-3-tiolanyl)-2-penem-antibiotika.
AT413382B (de) Verfahren zur herstellung von ceftriaxon unter verwendung eines silylierten 3-mercapto-2-methyl-(2,5-dihydro-6-hydroxy-5-ox - as)-triazins als schwefelnucleophil
DE4028666A1 (de) Heteroatome enthaltende, tricyclische verbindungen, verfahren zu ihrer herstellung und ihre verwendung
DE4028676A1 (de) Heteroatome enthaltende, tricyclische verbindungen, verfahren zu ihrer herstellung und ihre verwendung
DE4028677A1 (de) Heteroatome enthaltende, tricyclische verbindungen, verfahren zu ihrer herstellung und ihre verwendung
DE4028675A1 (de) Heteroatome enthaltende, tricyclische verbindungen, verfahren zu ihrer herstellung und ihre verwendung
DE4028667A1 (de) Heteroatome enthaltende, tricyclische verbindungen, verfahren zu ihrer herstellung und ihre verwendung

Legal Events

Date Code Title Description
8364 No opposition during term of opposition